EHPL – European Health & Pharmaceutical Law Review

The European Health & Pharmaceutical Law Review (EHPL) identifies and analyses important legal and regulatory developments on the national, EU and international level. It is primarily concerned with pharmaceutical law, medicines law and issues related to the work of the European Medicines Agency (EMA).

Furthermore, it provides an overview of and critically examines judgments and directives that shape the interpretation and application of EU pharmaceutical law and policy, including those by the European Medicines Agency (EMA), European Courts, international courts and tribunals such as the WTO’s Dispute Settlement Body, and higher national courts.

Managing Editor

Jakob Wested, University of Copenhagen, Denmark

Associate Editors

Deepaloke Chatterjee, Clifford Chance
Vladimir Murovec, Osborne Clarke
Giuseppe Ragucci, Simmons & Simmons

Editorial Board

Ulrich M. Gassner, University of Augsburg, Germany
Richard S. Goldberg, Durham University, UK
Leigh Hancher, University of Tilburg, Netherlands / Allen & Overy, Brussels, Belgium
Isabelle Huys, KU Leuven, Belgium
Tomasz Jablonski, European Medicines Agency, Amsterdam, Netherlands
Els Janssens, Baker McKenzie, Brussels, Belgium
Eveline Van Keymeulen, Latham & Watkins, Brussels, Belgium
Anastasiya Kiseleva, Vrije Universiteit Brussel
Trudo Lemmens, University of Toronto, Canada
Robert Madelin, Foresight International Policy and Regulatory
Timo Minssen, University of Copenhagen, Denmark
George Peretz, Monckton Chambers, London, UK
Vincenzo Salvatore, University of Insubria / Simmons & Simmons
Florian Schmidt, European Commission, Brussels, Belgium
Claudia Seitz, Private University in the Principality of Liechtenstein (UFL) / University of Ghent
Santa Slokenberga, Uppsala University, Sweden

Executive Editor

Jakob McKernan, Lexxion Publisher, Berlin

In order to establish itself as a forum for dialogue between different stakeholders in pharmaceutical regulation and governance, EHPL invites contributions from academics, practitioners, regulators and civil society representatives.

Topics covered by EHPL include:

• Pharmaceutical law and policy in all jurisdictions (regional, national, international);
• Medicines law
• Commission decisions (EMA opinions) and regulatory guidelines;
• National, EU, and international jurisprudence;
• Medical devices;
• Borderline cases: pharmaceuticals/food/cosmetics/chemicals
• Patents /trademarks;
• Health technology assessment and pricing/reimbursement;
• Digital health/big data;

All contributions will be subject to double blind peer-review before acceptance for publication and are required to conform to the author guidelines.

The quarterly journal addresses everyone who is concerned with pharmaceutical law and policy issues such as academics (in the field of medicines law, regulatory science, and other relevant research fields), legal practitioners in national and international law firms, regulators such government officials working in EU  and national public administration, judges and legal experts in domestic, European and international courts, consultancies, business people in the EU and beyond as well as stakeholder organisations representing professionals, patients, and civil society.

Each issue of EHPL will be a balanced mixture of original research articles, first-hand country or thematic policy reports, timely case annotations on important ECJ/GC rulings and other international/national court judgments, book reviews as well as other information material and updates, including opinions, case summaries or event reports.

The advertising prices are valid from January 2023. Please provide the advert in a PDF-X-1a format + 3 mm bleed (without crop marks).

Inserts/Supplements have to be delivered at least one week prior to publication date. Delivery address:

Schaltungsdienst Lange oHG
z.Hd. Fr. Schulz, Beilage EHPL _/2024 (Please state issue number.)
Zehrensdorfer Straße 11
12277 Berlin · Germany

Schedule 2024

(Changes excepted.)